Latest Innovation News

MoneyMe ended FY26 with a loan book exceeding $2 billion and achieved positive Normalised NPAT in the second half, supported by strong originations and improved credit metrics.

Praemium’s total Funds Under Administration surged 21% to $77.9 billion in FY26, driven by strong platform net inflows and robust growth in non-custodial portfolio administration.

WiseTech Global is acquiring FRDM.ai for $10 million upfront to accelerate its VerifyWise platform, enhancing multi-tier supply chain risk and compliance monitoring with AI-powered insights.

Beach Energy delivered a solid FY26 with 19.4 MMboe production, a record 18 months without injuries, and a key Otway Basin asset sale freeing $500 million capital.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Nanoveu’s ECS-DoT edge-AI chip has proven its mettle in live drone trials with up to 51% energy efficiency gains, while the acquisition of Spinoff Robotics adds proprietary drone platforms and engineering talent to accelerate commercialisation.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.

Pure Resources has achieved a key early milestone with Oak Ridge National Laboratory confirming the recovery of heavy rare earth elements from garnet concentrate at its Garnet Hills Project. While still at proof-of-concept stage, this validates the potential for a new source of critical minerals.